Identifying genetic markers for splenic lymphoma
Official title: Genomic biomarkers of splenic lymphoma
Funded at Sloan-Kettering Inst Can Research · NIH-10994066 · Data updated 2026-11-12
This study is looking for specific genetic markers in the blood of people with splenic marginal zone lymphoma (SMZL) to help doctors diagnose the cancer earlier and more accurately, so patients can get the right treatment without needing surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | October 1, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $452,854 |
| NIH project number | 5R01CA255655-06 |
| Project ID | NIH-10994066 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with or suspected to have splenic marginal zone lymphoma.
✕Less likely to help
Patients with other types of lymphoma or those who do not have any splenic involvement may not benefit from this research.
What this research studies
This research focuses on splenic marginal zone lymphoma (SMZL), a type of cancer affecting the spleen. It aims to develop reliable genomic biomarkers that can be detected in peripheral blood, allowing for earlier and more accurate diagnosis of the disease. By utilizing whole genome and exome sequencing, the study seeks to identify specific genetic alterations associated with SMZL, which could improve diagnostic accuracy and reduce the need for invasive procedures like splenectomy. Patients will be monitored for these biomarkers to facilitate timely intervention.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and better treatment options for patients with splenic lymphoma.
How similar studies have gone: Previous research has shown promise in using genomic biomarkers for cancer diagnosis, indicating potential success for this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Elenitoba-Johnson, Kojo S. J. — Sloan-Kettering Inst Can Research
- Study coordinator: Elenitoba-Johnson, Kojo S. J.
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.